MYOV - Urovant Sciences: Still A Hidden Gem With Multiple Catalysts Approaching

Overview

Urovant Sciences (NASDAQ: UROV) is a clinical stage biopharmaceutical company focused on the development and commercialization of its lead product candidate, vibegron, an oral, once-daily, small molecule beta-3 agonist, for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia (BPH), and abdominal pain due to irritable bowel syndrome (IBS).

We previously initiated coverage of Urovant Sciences in January. It has since underperformed the broader biotech market as it has participated in the sell off triggered by the pandemic, but underperformed during the recovery. It remains our highest conviction